scholarly journals Effect of Chelators on the Pharmacokinetics of 99mTc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA)

2013 ◽  
Vol 56 (15) ◽  
pp. 6108-6121 ◽  
Author(s):  
Sangeeta Ray Banerjee ◽  
Mrudula Pullambhatla ◽  
Catherine A. Foss ◽  
Alexander Falk ◽  
Youngjoo Byun ◽  
...  
Keyword(s):  
Imaging Agents ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

scholarly journals Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer

2008 ◽  
Vol 51 (24) ◽  
pp. 7933-7943 ◽  
Author(s):  
Ying Chen ◽  
Catherine A. Foss ◽  
Youngjoo Byun ◽  
Sridhar Nimmagadda ◽  
Mrudula Pullambhatla ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Imaging Agents ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

scholarly journals Synthesis and biological evaluation of substrate-based imaging agents for the prostate-specific membrane antigen

2013 ◽  
Vol 21 (5) ◽  
pp. 565-573 ◽  
Author(s):  
Youngjoo Byun ◽  
Mrudula Pullambhatla ◽  
Haofan Wang ◽  
Ronnie C. Mease ◽  
Martin G. Pomper
Keyword(s):  
Biological Evaluation ◽  
Imaging Agents ◽  
Prostate Specific Membrane Antigen ◽  
Synthesis And Biological Evaluation ◽  
Specific Membrane

scholarly journals Biomarkers in Prostate-Specific Membrane Antigen Theranostics

Diagnostics ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1108
Author(s):  
Panagiotis J. Vlachostergios ◽  
Ioannis Zachos ◽  
Vassilios Tzortzis
Keyword(s):  
Prostate Cancer ◽  
Imaging Agents ◽  
Surrogate Markers ◽  
Prostate Specific Membrane Antigen ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Specific Membrane ◽  
Major Target

Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of 177Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular.

Sign in / Sign up

Export Citation Format

Share Document